ETFChannel.com
IRWD Description — Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals is a gastrointestinal (GI), healthcare company focusing on developing the treatment of GI diseases. Co.'s commercial product, LINZESS® (linaclotide), a guanylate cyclase type C agonists, is indicated for adult men and women suffering from irritable bowel syndrome with constipation, or chronic idiopathic constipation. In addition, Co. is developing MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients with abdominal pain associated with certain GI diseases. Co. is also developing IW-3718, a gastric retentive formulation of a bile acid sequestrant for the potential treatment of refractory gastroesophageal reflux disease.

Company Name: 
Ironwood Pharmaceuticals Inc
Website: 
www.ironwoodpharma.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding IRWD: 
39
Total Market Value Held by ETFs: 
$295,998,925.88
Total Market Capitalization: 
$1,969,000,000
% of Market Cap. Held by ETFs: 
15.03%
 ETF   IRWD Weight   IRWD Amount 
 XBI   0.66%   $48,248,539         
 VTI   0.00%   $47,194,680         
 VB   0.03%   $41,199,875         
 IWM   0.06%   $39,525,178         
 VXF   0.02%   $28,240,910         
 VBK   0.07%   $26,026,348         
 IBB   0.14%   $15,229,495         
 IWO   0.12%   $14,149,825         
 PBE   2.49%   $7,445,945         
 VHT   0.03%   $5,763,949         
List of all 39 ETFs holding IRWD »
Quotes delayed 20 minutes

Hold (2.40 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts Forecast:
IRWD Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding IRWD | Ironwood Pharmaceuticals Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.